MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Floxuridine

CAS No. : 50-91-9

MCE 站：Floxuridine

产品活性：Floxuridine (5-Fluorouracil 2'-deoxyriboside) 是一种嘧啶类似物，被也是一种抗肿瘤代谢物 (oncology antimetabolites)。Floxuridine 通过激活 ATM 和 ATR 检查点信号通路，在体外抑制 Poly(ADP-Ribose) polymerase 并诱导 DNA 损伤。Floxuridine 是一种非常有效的金黄色葡萄球菌感染抑制剂并且可以诱导细胞凋亡 (apoptosis)。Floxuridine 具有抗 HSV 和 CMV 病毒的作用。

研究领域：Cell Cycle/DNA Damage  |  Anti-infection  |  Apoptosis

作用靶点：Nucleoside Antimetabolite/Analog  |  DNA/RNA Synthesis  |  Bacterial  |  CMV  |  HSV  |  Apoptosis

In Vitro: Floxuridine?(0-25 μM; 4-24 hours) is affectd by inhibitors of PARP and its sensitivity of ovarian cancer cells is enhanced. Co-exposed to FdUrd and the PARP inhibitor markedly increases killing cell numbers when its compare to treatment alone in ovarian cancer cells.
Floxuridine?(300 μM; 4-24 hours) increases p-Chk1 and p-Chk2 in ovarian cancer cell lines. It may induce DNA damage and activate the ATM and ATR checkpoint signaling pathways.
Floxuridine?(0-2.5 μM; 24 hours) causes a G1/S-phase arrest and following removal of the FdUrd, the G1/S-phase-arrested cells moved synchronously through S phase and into G2/M.
Floxuridine is against Mueller Hinton Broth and Tryptic Soy Broth with MIC values of 0.25?μM and 0.81?μM, respectively. It also reported to be a very potent inhibitor of staphylococcal growth (MIC, 0.025–0.00313?μM).

In Vivo: Floxuridine? (intraperitoneal injection; 0.5-1.25 mg/kg; once per day for 7 days or single dose) is sufficient to show statistically significant protection against?S. aureus?infection at 0.5 mg/kg for 7 days. In addition, 1.25?mg/kg single administration of the compound shows statistically significant protection against?S. aureus?infection.

相关产品：Covalent Screening Library Plus  |  Natural Product Like Compound Library  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Apoptosis Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Reprogramming Compound Library  |  Nucleotide Compound Library  |  Antibacterial Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Blood Cancer Compound Library  |  MG-132  |  LY294002  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Puromycin dihydrochloride  |  Paclitaxel  |  Cycloheximide  |  Y-27632 dihydrochloride  |  Acetylcysteine  |  Angiotensin II human  |  SP600125  |  5-Fluorouracil  |  Staurosporine  |  Dexamethasone  |  Bortezomib  |  Tamoxifen  |  2-Deoxy-D-glucose  |  Oxaliplatin  |  Gemcitabine  |  Verteporfin  |  Doxycycline (hyclate)  |  Decitabine  |  Actinomycin D  |  Temozolomide  |  G-418 disulfate  |  5-Azacytidine  |  BAY 11-7082  |  Etoposide  |  Mitomycin C

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。